This company has been marked as potentially delisted and may not be actively trading. Bioblast Pharma (ORPN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock ORPN vs. EYEN, KTTA, ZVSA, VRPX, CNSP, VCNX, RSLS, ONCT, PBLA, and PTPIShould you be buying Bioblast Pharma stock or one of its competitors? The main competitors of Bioblast Pharma include Eyenovia (EYEN), Pasithea Therapeutics (KTTA), ZyVersa Therapeutics (ZVSA), Virpax Pharmaceuticals (VRPX), CNS Pharmaceuticals (CNSP), Vaccinex (VCNX), ReShape Lifesciences (RSLS), Oncternal Therapeutics (ONCT), Panbela Therapeutics (PBLA), and Petros Pharmaceuticals (PTPI). These companies are all part of the "medical" sector. Bioblast Pharma vs. Eyenovia Pasithea Therapeutics ZyVersa Therapeutics Virpax Pharmaceuticals CNS Pharmaceuticals Vaccinex ReShape Lifesciences Oncternal Therapeutics Panbela Therapeutics Petros Pharmaceuticals Bioblast Pharma (NASDAQ:ORPN) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation. Does the MarketBeat Community favor ORPN or EYEN? Bioblast Pharma received 38 more outperform votes than Eyenovia when rated by MarketBeat users. Likewise, 78.23% of users gave Bioblast Pharma an outperform vote while only 64.21% of users gave Eyenovia an outperform vote. CompanyUnderperformOutperformBioblast PharmaOutperform Votes21278.23% Underperform Votes5921.77% EyenoviaOutperform Votes17464.21% Underperform Votes9735.79% Does the media refer more to ORPN or EYEN? In the previous week, Bioblast Pharma's average media sentiment score of 0.00 equaled Eyenovia'saverage media sentiment score. Company Overall Sentiment Bioblast Pharma Neutral Eyenovia Neutral Which has more risk and volatility, ORPN or EYEN? Bioblast Pharma has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Do analysts rate ORPN or EYEN? Eyenovia has a consensus price target of $2.00, suggesting a potential upside of 80.18%. Given Eyenovia's stronger consensus rating and higher probable upside, analysts plainly believe Eyenovia is more favorable than Bioblast Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioblast Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Eyenovia 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ORPN or EYEN more profitable? Bioblast Pharma has a net margin of 0.00% compared to Eyenovia's net margin of -114,639.41%. Bioblast Pharma's return on equity of 0.00% beat Eyenovia's return on equity.Company Net Margins Return on Equity Return on Assets Bioblast PharmaN/A N/A N/A Eyenovia -114,639.41%-1,108.24%-139.36% Which has preferable valuation and earnings, ORPN or EYEN? Bioblast Pharma has higher earnings, but lower revenue than Eyenovia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioblast PharmaN/AN/A-$5.94MN/AN/AEyenovia$31.83K48.57-$27.26M-$58.40-0.02 Do insiders & institutionals believe in ORPN or EYEN? 4.5% of Bioblast Pharma shares are owned by institutional investors. Comparatively, 25.8% of Eyenovia shares are owned by institutional investors. 7.1% of Eyenovia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryBioblast Pharma beats Eyenovia on 7 of the 12 factors compared between the two stocks. Remove Ads Get Bioblast Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORPN vs. The Competition Export to ExcelMetricBioblast PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$397,000.00$6.72B$5.53B$7.50BDividend YieldN/A2.85%4.87%4.05%P/E RatioN/A6.9923.1218.08Price / SalesN/A198.60360.0289.38Price / CashN/A65.6738.1634.64Price / Book0.135.926.473.99Net Income-$5.94M$142.37M$3.21B$247.18M Bioblast Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORPNBioblast PharmaN/A$0.95-6.3%N/A-75.0%$397,000.00N/A0.00N/AGap DownHigh Trading VolumeEYENEyenovia1.6877 of 5 stars$1.26-5.3%$2.00+58.7%-98.5%$1.76M$31,832.00-0.0240Gap DownKTTAPasithea Therapeutics0.6223 of 5 stars$1.38+10.4%N/A-84.1%$1.75MN/A0.003Positive NewsZVSAZyVersa Therapeutics0.1669 of 5 stars$0.73+1.7%N/A-91.5%$1.71MN/A0.002VRPXVirpax Pharmaceuticals1.492 of 5 stars$1.55-3.7%$75.00+4,738.7%-99.4%$1.65MN/A0.007CNSPCNS Pharmaceuticals1.3377 of 5 stars$1.41-13.5%$25.00+1,673.0%-99.8%$1.62MN/A-0.025Upcoming EarningsGap UpVCNXVaccinexN/A$0.61+10.9%N/A-92.2%$1.59M$388,000.00-0.0140Negative NewsGap DownRSLSReShape Lifesciences0.6878 of 5 stars$0.47-9.7%N/A-96.3%$1.56M$8.18M0.0050Upcoming EarningsPositive NewsHigh Trading VolumeONCTOncternal Therapeutics1.2655 of 5 stars$0.53flat$10.00+1,799.0%N/A$1.56M$790,000.00-0.0530Analyst ForecastPBLAPanbela TherapeuticsN/A$0.32-5.9%N/A-41.8%$1.55MN/A0.006Gap DownPTPIPetros Pharmaceuticals0.1867 of 5 stars$0.14+133.6%N/A-92.6%$1.53M$4.02M-0.0320Upcoming EarningsGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Eyenovia Competitors Pasithea Therapeutics Competitors ZyVersa Therapeutics Competitors Virpax Pharmaceuticals Competitors CNS Pharmaceuticals Competitors Vaccinex Competitors ReShape Lifesciences Competitors Oncternal Therapeutics Competitors Panbela Therapeutics Competitors Petros Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORPN) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioblast Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORPN Stock Free ORPN Stock Alerts